Immatics logo

Immatics

The Global Leader in Precision Targeting of PRAME

637 employees · est. 2000 · Germany

VS
Quentis Therapeutics logo

Quentis Therapeutics

Developing innovative immuno-therapeutics to combat ER stress and empower the immune system in the fight against cancer

est. 2016

Immatics is the older company (2000 vs 2016).

Side-by-Side Comparison

Immatics Quentis Therapeutics
Founded
2000 older 2016
Headquarters
Germany Not tracked yet
Employees
637 Not tracked yet
Industry
Not tracked yet Biotechnology, Health Care, Health and Wellness
Funding Stage
IPO Grant
Total Funding
$908.10M $49.00M
Funding Rounds
14 2
Services
Precision targeting of PRAME in over 50 types of cancer, Development of cell therapies and bispecific products Not tracked yet
Target Customers
Cancer patients with unmet medical needs, Healthcare professionals specializing in oncology, Research and academic institutions Not tracked yet
Taxonomy
Precision Medicine, Cancer Immunotherapy, TCR T-cell Therapies, TCR Bispecifics, Adoptive Cell Therapy, PRAME Targeting, Solid Tumor Treatment, Peptidomics, Tumor-associated Peptides, Biopharmaceutical, Clinical Pipeline, HLA-restricted Target Discovery, Cancer Biomarkers, Bispecific Development, TCR Discovery Immuno-therapeutics, ER Stress, Cancer Treatment, Immune System, Cancer Therapy, Innovative Treatments, Biopharmaceuticals, Oncology, Drug Development, Immunotherapy, Cancer Research
Website
immatics.com quentistx.com
Immatics logo

About Immatics

Immatics, founded in 2000 and headquartered in Germany, positions itself as a crucial player in the biotechnology sector. As the self-proclaimed "The Global Leader in Precision Targeting of PRAME", the company focuses on cancer treatment with a specialty in targeting PRAME—a protein expressed in ove...

Quentis Therapeutics logo

About Quentis Therapeutics

Quentis Therapeutics is a biotechnology startup founded in 2016 that is focused on developing innovative immuno-therapeutics to combat ER stress and empower the immune system in the fight against cancer. The company's slogan, "Developing innovative immuno-therapeutics to combat ER stress and empower...

Be first to know when either one moves

Funding rounds, hiring surges, leadership changes and stack switches at Immatics and Quentis Therapeutics — tracked continuously, sent the day they land.

Watch both — free

Funding, hiring, leadership and stack changes at Immatics and Quentis Therapeutics — by email.

Frequently Asked Questions

Immatics — The Global Leader in Precision Targeting of PRAME. Quentis Therapeutics — Developing innovative immuno-therapeutics to combat ER stress and empower the immune system in the fight against cancer. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
Immatics has raised $908.10M while Quentis Therapeutics has raised $49.00M.
Immatics and Quentis Therapeutics operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare Immatics with someone else

Start typing a company name or domain.

One analytics cookie (Google Analytics). Cookie Policy